Immunotherapy specialist Targovax today announces completion of a 70 MNOK financing, mainly from new investors. The share issue was significantly oversubscribed.

CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to develop Targovax as a company“.